Key clinical point: A set of clinical factors predict risk of severe immune-related adverse events among oncology patients treated with immune checkpoint inhibitors.
Major finding: The risk of events was higher with combination immunotherapy (odds ratio, 2.44). Risk fell with age (OR, 0.98) and was lower for patients with melanoma (OR, 0.71), renal cell carcinoma (OR, 0.71), and other cancers (OR, 0.50), compared with lung cancer.
Study details: A U.S. retrospective population-level cohort study using claims data for 14,378 oncology patients treated with immune checkpoint inhibitors.
Disclosures: The study did not receive any specific funding. Mr. Murphy disclosed no relevant conflicts of interest.
Murphy W et al. SITC 2020, Abstract 854.